YH002 has shown favourable safety and anti-tumour activity against solid tumours. Credit: National Cancer Institute / Unsplash.

Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. 

According to the deal, the worldwide rights for developing and marketing intratumoral combination treatment containing Eucure’s YH002 and two additional active ingredients of the Syncrovax therapy will be acquired by Syncromune. 

Related Company Profiles

View all

Eucure is eligible to receive upfront cash payment indicating the molecules’ anticipated clinical value, as well as development and regulatory milestone payments from Syncromune.

Additionally, Syncromune will make royalty payments and other incentives depending on the Syncrovax combination treatment’s long-term commercial value. 

Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing.

See Also:

A co-stimulating molecule for the OX40 target, YH002 has shown favourable safety and anti-tumour activity against solid tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Syncromune president and CEO Eamonn Hobbs said: “We are excited to enter into an exclusive licensing agreement with Eucure/Biocytogen. 

“This license agreement is an important step in the development of our proprietary Syncrovax platform and further supports Syncromune’s strategy to maximise our platform to build a sustainable cancer therapeutics company.”

The Syncrovax platform is a tailored cancer therapy under development to streamline intratumoral immunotherapy to treat metastatic solid tumour cancers. 

This technology aims to create a custom-made autologous cancer vaccine utilising the cancer antigens of the patient.